Wave Life Sciences Ltd. - Ordinary Shares (OQ:WVE)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Apr 23, 2024 08:30 am ET

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA...

Mar 27, 2024 08:30 am ET

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...

Mar 06, 2024 07:30 am ET

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the fourth quarter and full year ended December...

Feb 28, 2024 08:30 am ET

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6,...

Feb 27, 2024 08:30 am ET

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced its upcoming presentations at the 2024 Muscular Dystrophy Association...

Jan 08, 2024 08:00 am ET

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced key 2024 milestones across its clinical programs, growing pipeline,...

Jan 03, 2024 08:30 am ET

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

Dec 15, 2023 08:30 am ET

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the Phase 2 FORWARD-53 clinical...

Dec 07, 2023 08:31 am ET

Thinking about buying stock in Realty Income, Eyepoint Pharmaceuticals, Altisource Asset Management, Reviva Pharmaceuticals, or Wave Life Sciences?

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for O, EYPT, AAMC, RVPH, and WVE.

Dec 07, 2023 07:00 am ET

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public...

Dec 06, 2023 04:10 pm ET

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100...

Dec 06, 2023 04:08 pm ET

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in healthy volunteers in the...

Nov 22, 2023 08:30 am ET

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

Nov 09, 2023 07:30 am ET

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30,...

Nov 03, 2023 04:05 pm ET

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday,...

Sep 28, 2023 04:15 pm ET

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today held a virtual analyst and investor R&D Day, which highlighted the...

Sep 25, 2023 08:30 am ET

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

Sep 06, 2023 08:30 am ET

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 05, 2023 07:30 am ET

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the submission of its first clinical trial application (CTA)...

Aug 03, 2023 07:30 am ET

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30, 2023,...

Jul 27, 2023 08:30 am ET

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

Jun 26, 2023 08:30 am ET

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 2000®...

May 23, 2023 07:30 am ET

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating...

May 16, 2023 08:30 am ET

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its leading RNA editing capability and its...

May 03, 2023 07:30 am ET

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 2023...

Apr 26, 2023 08:30 am ET

Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday,...

Apr 20, 2023 08:30 am ET

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the publication of preclinical data for the company’s small...

Mar 29, 2023 08:00 am ET

Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Mar 22, 2023 07:30 am ET

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year...

Mar 02, 2023 08:30 am ET

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Feb 09, 2023 04:05 pm ET

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Dec 19, 2022 07:37 am ET

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today a positive update from the initial cohort of the Phase...

Dec 13, 2022 07:41 am ET

Thinking about buying stock in Magenta Therapeutics, Ventyx Biosciences, Wave Life Sciences, Oncternal Therapeutics, or EHang Holdings?

NEW YORK, Dec. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGTA, VTYX, WVE, ONCT, and EH.

Dec 13, 2022 07:30 am ET

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, and GSK plc (LSE/NYSE: GSK) today announced a strategic collaboration to...

Nov 10, 2022 07:30 am ET

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30,...

Nov 09, 2022 08:30 am ET

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Nov 03, 2022 08:30 am ET

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Oct 03, 2022 08:30 am ET

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight oligonucleotide chemistry advancements...

Sep 28, 2022 01:30 pm ET

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today hosted a virtual event, “Towards the Clinic: Spotlight on RNA Editing...

Sep 27, 2022 08:30 am ET

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Sep 20, 2022 07:30 am ET

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive update to the ongoing Phase 1b/2a SELECT-HD...

Sep 16, 2022 08:30 am ET

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast on Wednesday,...

Aug 12, 2022 08:30 am ET

Thinking about buying stock in Unity Biotechnology, Payoneer Global, Toast, Wave Life Sciences, or Hippo?

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UBX, PAYO, TOST, WVE, and HIPO.

Aug 11, 2022 07:30 am ET

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30,...

Jul 28, 2022 08:30 am ET

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Jun 14, 2022 09:00 am ET

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “Offering”) of...

May 25, 2022 08:30 am ET

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

May 12, 2022 07:30 am ET

Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,...

May 10, 2022 08:30 am ET

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

May 05, 2022 08:30 am ET

Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Apr 25, 2022 08:30 am ET

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the publication of preclinical data for WVE-004, the...

Apr 19, 2022 08:30 am ET

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Apr 04, 2022 07:30 am ET

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive update to the ongoing Phase 1b/2a FOCUS-C9 trial...

Mar 21, 2022 08:30 am ET

Wave Life Sciences to Present at Stifel 2022 CNS Days

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Mar 21, 2022 07:05 am ET

Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its...

Mar 15, 2022 08:30 am ET

Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will highlight its therapeutic A-to-I(G) RNA base...

Mar 07, 2022 11:14 am ET

Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the publication of preclinical proof-of-concept data for...

Mar 03, 2022 07:30 am ET

Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year...

Feb 24, 2022 08:30 am ET

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Feb 09, 2022 08:30 am ET

Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Feb 02, 2022 04:05 pm ET

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced two publications in the journal Nucleic Acids Research...

Jan 25, 2022 10:07 am ET

ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program

NEW YORK, Jan. 25, 2022 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered to support Wave Life Sciences' FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS). The partnership provides an investment from ADDF and AFTD that will support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers in FOCUS-C9, potentially

Dec 23, 2021 06:00 pm ET

Vintage Wine Estates marks eight years and one million meals donated through its Angels Share campaign to fight food insecurity

SANTA ROSA, Calif., Dec. 23, 2021 /PRNewswire/ -- Vintage Wine Estates, Inc. (NASDAQ: VWE) (TSX: VWE.U) (TSX: VWE.WT.U) ("VWE" or the "Company"), one of the fastest-growing wine producers in the U.S. with an industry leading direct-to-customer platform announced a milestone of one million meals donated by its Angels Share campaign to fight food insecurity.

Nov 10, 2021 07:30 am ET

Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30,...

Nov 08, 2021 04:05 pm ET

Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Nov 01, 2021 08:30 am ET

Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Oct 18, 2021 05:00 pm ET

Wave Life Sciences and Takeda Amend CNS Collaboration

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced an amendment to its ongoing collaboration with Takeda...

Sep 29, 2021 08:30 am ET

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in a Phase 1b/2a clinical trial...

Sep 28, 2021 04:05 pm ET

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today presented new data for its ADAR-mediated RNA editing capability (ADAR...

Sep 22, 2021 04:05 pm ET

Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Sep 09, 2021 08:30 am ET

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the company’s Phase 1b/2a...

Sep 08, 2021 08:30 am ET

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing capability,...

Sep 07, 2021 04:05 pm ET

Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Sep 07, 2021 08:30 am ET

Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing (“ADAR...

Aug 05, 2021 07:30 am ET

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30,...

Jul 26, 2021 04:05 pm ET

Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Jul 20, 2021 08:00 am ET

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that multiple participants have initiated dosing in the...

Jun 02, 2021 04:52 pm ET

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the first proof-of-concept preclinical data for its ADAR...

May 28, 2021 08:30 am ET

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

May 13, 2021 07:30 am ET

Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,...

May 10, 2021 04:05 pm ET

Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

May 03, 2021 04:05 pm ET

Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Mar 29, 2021 04:05 pm ET

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced data from the Phase 1b/2a PRECISION-HD2 and PRECISION-HD1...

Mar 19, 2021 08:00 am ET

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Mar 04, 2021 07:00 am ET

Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year...

Feb 23, 2021 08:00 am ET

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Feb 16, 2021 05:00 pm ET

Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Jan 11, 2021 08:00 am ET

Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced key upcoming milestones for 2021, including the initiation...

Dec 02, 2020 08:00 am ET

Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human...

Nov 10, 2020 08:00 am ET

Wave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Nov 09, 2020 07:30 am ET

Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September...

Oct 26, 2020 04:05 pm ET

Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Sep 28, 2020 04:05 pm ET

Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Sep 23, 2020 07:00 am ET

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public...

Sep 22, 2020 04:01 pm ET

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of...

Sep 15, 2020 07:30 am ET

Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it will highlight its ADAR (adenosine deaminases...

Sep 10, 2020 04:25 pm ET

Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Aug 10, 2020 07:30 am ET

Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30,...

Aug 06, 2020 08:00 am ET

Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will hold an Analyst and Investor Research Webcast...

Jul 27, 2020 04:05 pm ET

Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

May 26, 2020 04:05 pm ET

Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

May 18, 2020 07:30 am ET

Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, PhD, as Senior Vice...

May 11, 2020 07:30 am ET

Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,...

Apr 29, 2020 04:05 pm ET

Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Mar 02, 2020 06:45 am ET

Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year...

Feb 19, 2020 08:00 am ET

Wave Life Sciences to Present at the Cowen and Company 40th Annual Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

Feb 18, 2020 08:00 am ET

Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will present preclinical data from its...

Feb 13, 2020 08:05 am ET

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

Dec 30, 2019 07:00 am ET

Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced topline data from the ongoing Phase 1b/2a PRECISION-HD2...

Dec 16, 2019 07:00 am ET

Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for...

Nov 05, 2019 04:05 pm ET

Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30,...

Sep 16, 2019 07:30 am ET

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has...

Sep 06, 2019 08:30 am ET

Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will host a Research Day for analysts and investors on...

Sep 05, 2019 07:30 am ET

Wave Life Sciences Expands Board of Directors with Three New Appointments

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Amy Pott, Heidi L. Wagner, JD, and Mark...

Aug 26, 2019 04:05 pm ET

Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

Aug 06, 2019 07:30 am ET

Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Mark Baldry as Chief Commercial Officer....

Jul 29, 2019 04:05 pm ET

Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30,...

Jun 27, 2019 08:00 am ET

Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from...

Jun 27, 2019 08:00 am ET

Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and...

Jun 12, 2019 08:00 am ET

Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara, MD, MPH, Chief Medical Officer, will...

May 22, 2019 04:15 pm ET

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

May 10, 2019 07:30 am ET

Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,...

Apr 16, 2019 07:00 am ET

Report: Developing Opportunities within Hilton Worldwide, Arthur J. Gallagher, WAVE Life Sciences, Hertz Global, Novavax, and Presidio — Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hilton Worldwide Holdings Inc. (NYSE:HLT), Arthur J. Gallagher & Co....

Apr 16, 2019 07:00 am ET

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the final results from its Phase 1 clinical trial of...

Apr 12, 2019 08:00 am ET

Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference

Apr 10, 2019 07:00 am ET

Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today provided an update on the timing of the topline data readout from its...

Mar 25, 2019 08:00 am ET

Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and...

Mar 06, 2019 08:00 am ET

Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

Mar 01, 2019 07:30 am ET

Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today reported financial results for the fourth quarter and full year ended...

Feb 22, 2019 07:45 am ET

Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic Packaging Holding Company (NYSE:GPK), Vulcan Materials Company...

Feb 12, 2019 12:17 pm ET

Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.

Feb 12, 2019 12:17 pm ET

Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

Jan 24, 2019 08:48 am ET

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public...

Jan 23, 2019 04:23 pm ET

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of...

Jan 03, 2019 08:00 am ET

Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Dec 06, 2018 07:30 am ET

Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)

Nov 09, 2018 07:30 am ET

Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 08, 2018 08:59 am ET

Wave Life Sciences to Present at the Jefferies 2018 London Healthcare Conference

Oct 24, 2018 07:35 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within Inter Parfums, United Continental, Turning Point Brands, TPI Composites, Nelnet, and WAVE Life Sciences — New Research Emphasizes Ec

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Inter Parfums, Inc. (NASDAQ:IPAR), United Continental Holdings, Inc....

Oct 09, 2018 07:30 am ET

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Sep 20, 2018 08:00 am ET

Wave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings

Aug 16, 2018 08:00 am ET

Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201

Aug 09, 2018 08:00 am ET

Wave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update

Jul 02, 2018 08:00 am ET

Wave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201

Jun 25, 2018 04:37 pm ET

Wave Life Sciences to Present at Parent Project Muscular Dystrophy Annual Conference

Jun 07, 2018 08:20 am ET

Market Trends Toward New Normal in Gridsum Holding, Wave Life Sciences, KT, BlackBerry, Kosmos Energy, and Hovnanian Enterprises — Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gridsum Holding (NASDAQ:GSUM), Wave Life Sciences Ltd. (NASDAQ:WVE), KT...

May 31, 2018 05:11 pm ET

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

May 09, 2018 08:00 am ET

Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update

May 07, 2018 08:00 am ET

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

Apr 17, 2018 08:00 am ET

Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) --

Apr 11, 2018 08:15 am ET

Investor Expectations to Drive Momentum within Xcerra, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, WAVE Life Sciences, Hoegh LNG Partners LP, Mesoblast, and Intuitive Surgical — Discovering Un

NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) --

Apr 10, 2018 08:00 am ET

Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders

CAMBRIDGE, Mass. and TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., a biotechnology company that is...

Apr 05, 2018 04:41 pm ET

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

Mar 16, 2018 07:50 am ET

New Research: Key Drivers of Growth for Oaktree Specialty Lending, Retail Opportunity Investments, WAVE Life Sciences, Siliconware Precision Industries, UNIVERSAL INSURANCE HOLDINGS INC, and Sina — Fa

NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree Specialty Lending Corp. (NASDAQ:OCSL), Retail...

Mar 12, 2018 08:00 am ET

Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update

Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018

Feb 20, 2018 07:00 am ET

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support

Feb 08, 2018 07:30 am ET

Wave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive...

Dec 11, 2017 07:00 am ET

Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND

Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD

Nov 09, 2017 08:00 am ET

Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update

Nov 06, 2017 07:00 am ET

Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy (DMD)

Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the initiation of a global Phase 1 clinical trial for WVE-210201 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in

Oct 26, 2017 04:00 pm ET

Wave Life Sciences Unveils New Manufacturing Facility in Lexington, MA

Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the public opening of its new 90,000 square foot state-of-the-art manufacturing facility and office space in Lexington, Massachusetts. The unveiling of the new facility was celebrated today with a ribbon cutting ceremony featuring local officials and leaders from the Massachusetts life sciences industry and rare disease communities.

Oct 12, 2017 07:00 am ET

Wave Life Sciences to Present at the Jefferies Gene Technology Investor Summit

Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies Gene Technology Investor Summit on Thursday, October 12, 2017 at 8:20 A.M. ET in New York, New York.

Jan 05, 2017 10:13 am ET

Satsuma Pharmaceuticals Spins Out from Shin Nippon Biomedical Laboratories (SNBL) with Funding from Leading Institutional Life Science Investors

SAN FRANCISCO, Jan. 5, 2017 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a leader in developing best-in-class therapies to address the unmet needs of migraine sufferers, today announced the closing of a $12 million Series A financing co-led by RA Capital Management and TPG Biotech. RA Capital Portfolio Manager and Managing Director, Rajeev Shah, and TPG Biotech Partner and Managing Director, Heath Lukatch, Ph.D., have joined Satsuma's board of directors.

Ad blocking detected

Wave Life Sciences Ltd. - Ordinary Shares (OQ:WVE)

Business Focus: N/A